Besides recaps, has anyone seen a series B/C that's lower $ in than the previous round? Feels like its assumed it has to be larger even when its not best.
Replying to @micahjay1
lots in biopharma-- but almost always an inside round to boost to a proofpoint to begin the IPO grind
5:37 PM - 12 Nov 2019
0 replies
0 retweets
3 likes
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.